TECHNOLOGY BRIEFING

TECHNOLOGY BRIEFING

Thursday, June 9, 2005

Hacking

Extradition Sought in Military Case

A Briton accused in what U.S. authorities call the biggest successful hacking effort against U.S. military computer networks was freed on bail after a court appearance in London. Gary McKinnon, 39, left, is accused of installing software allowing him to control military computers, including the Army's network for Washington. Lawyers for McKinnon, who was first arrested in the case nearly three years ago and then released, said he would fight extradition. It was not clear why U.S. officials took so long to seek extradition.

Legal

HP Settles Patent Lawsuit

Hewlett-Packard said it has settled a patent-infringement lawsuit it filed against inkjet cartridge remanufacturer InkCycle for an undisclosed sum. Hewlett-Packard sued InkCycle in March, alleging it was selling refilled cartridges under the Staples brand that infringed on Hewlett's ink patents.

Wireless Biller Says Verdict Could Sink It

A company that provides billing services to some of the nation's largest cellular carriers says it could end up in bankruptcy court or out of business if it fails to get a $128 million patent-infringement award overturned.

Last month, a federal jury in Boston ruled against Boston Communications Group in a lawsuit filed in 2000 by Freedom Wireless in a dispute over billing technology for prepaid calling.

Boston Communications alleges that Phoenix-based Freedom Wireless failed to accurately state what related technologies already existed when it sought a patent for its billing software.

Freedom Wireless began patenting technology in 1994 that allows customers making prepaid calls to avoid dialing identification codes or calling toll-free numbers.

Stocks

ImClone Shares Jump on News From Study

Shares of biotechnology firm ImClone Systems rose 17 percent after the company announced that a late-stage study showed its Erbitux drug to be effective in preventing the spread of head and neck cancer. The shares rose $5.11, to $35.27, on the news.

Erbitux is approved to treat colorectal cancer. Study results saying it might treat head and neck cancer were released last year, but now they have been confirmed by an independent review committee, said Jim Reddoch, senior biotech analyst with Friedman, Billings, Ramsey Group of Arlington.

Reddoch estimates head and neck cancer to be about a $400 million market with no existing drug treatments.

Company Watching Your E-Mail?

In washingtonpost.com's Security Fix blog: A new report finds that more mid- to large-size companies are actively monitoring employees' e-mails. http://www.washingtonpost.com/securityfix

Compiled from staff and news service reports.


© 2005 The Washington Post Company